These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34454901)

  • 1. Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations.
    Chow OS; Villena-Vargas J; Nasar A; Sun B; Harrison S; Lee B; Port JL; Altorki NK; Stiles BM
    Ann Thorac Surg; 2022 Sep; 114(3):905-910. PubMed ID: 34454901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Lee KH; Chung JH; Cho S; Lee JS; Kim H
    Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
    Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
    Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
    Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
    Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
    J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
    Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
    Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Katsumata S; Shimokawa M; Hamada A; Haratake N; Nomura K; Fujino K; Yoshikawa M; Suzawa K; Shien K; Suda K; Ohara S; Fukuda S; Kinoshita F; Hayasaka K; Notsuda H; Takamori S; Muto S; Takanashi Y; Mizuno K; Kawase A; Hayakawa T; Sekihara K; Toda M; Matsuo S; Takegahara K; Hashimoto M; Nakahashi K; Endo M; Ozawa H; Fujikawa R; Tomioka Y; Namba K; Matsubara T; Suzuki J; Watanabe H; Takada K; Hoshino H; Kaiho T; Toyoda T; Kouki Y; Shiono S; Soh J; Ohde Y
    Eur J Cancer; 2024 Apr; 201():113951. PubMed ID: 38417299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma.
    Matsumura Y; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Hoshino M; Osugi J; Higuchi M; Suzuki H
    Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):690-695. PubMed ID: 29049789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations.
    Chen T; Wen J; Li Y; Deng J; Zhong Y; Hou L; She Y; Xie D; Chen C
    Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38001033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.